STOCK TITAN
  1. Home
  2. News
  3. Clinical Trials

Clinical Trials News LIVE

Step into the labs where medical history is made. Our clinical trial news feed brings you to the forefront of scientific discovery and its market implications.

Each trial result is a potential game-changer. Whether it's a Phase 3 triumph or an unexpected study termination, we've got you covered.

Don't just follow biotech trends – anticipate them. With our real-time clinical trial updates, you're positioned to react to scientific progress as it happens, potentially before the broader market catches on.

1

NEWS
TODAY
check them out

-

NEWS ENHANCED BY
RHEA-AI
Who is Rhea? Read More
NEWS BY EXCHANGE
NYSE Nasdaq OTC

Stock News Live Feed

Today's News - Full List
IMPACT
SENTIMENT
CGTX : Nasdaq
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
conferences clinical trial
IMPACT
SENTIMENT
NAMS : Nasdaq NAMSW : Nasdaq
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
clinical trial
IMPACT
SENTIMENT
PMN : Nasdaq
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
clinical trial low float
IMPACT
SENTIMENT
FSXLF : OTC
Great Pacific Gold Completes Phase 2 Sampling Program at Kesar Creek Project in Papua New Guinea
clinical trial
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
clinical trial
IMPACT
SENTIMENT
CALT : Nasdaq
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
clinical trial
IMPACT
SENTIMENT
IMMX : Nasdaq
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
clinical trial
IMPACT
SENTIMENT
INO : Nasdaq
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
clinical trial
IMPACT
SENTIMENT
ATNM : NYSE NYSE : NYSE
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
clinical trial fda approval
IMPACT
SENTIMENT
CRVS : Nasdaq
Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
clinical trial
IMPACT
SENTIMENT
INZY : Nasdaq
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
clinical trial
IMPACT
SENTIMENT
ENVB : Nasdaq
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
clinical trial low float
IMPACT
SENTIMENT
CLLMF : OTC
Collective Completes Phase 1 Exploration Program at the Princeton Copper Project
clinical trial
IMPACT
SENTIMENT
WINT : Nasdaq
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
clinical trial low float
IMPACT
SENTIMENT
TNXP : Nasdaq
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
clinical trial fda approval low float high short
IMPACT
SENTIMENT
CKPT : Nasdaq FBIO : Nasdaq
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
clinical trial fda approval
IMPACT
SENTIMENT
ALT : Nasdaq
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
clinical trial high short
IMPACT
SENTIMENT
ACIU : Nasdaq
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
clinical trial fda approval
IMPACT
SENTIMENT
BCDA : Nasdaq
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
clinical trial low float
IMPACT
SENTIMENT
CMMB : Nasdaq
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
clinical trial
IMPACT
SENTIMENT
OCGN : Nasdaq
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
clinical trial
IMPACT
SENTIMENT
TEVA : NYSE
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
clinical trial
IMPACT
SENTIMENT
DASTY : OTC
Dassault Systèmes: Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
clinical trial
IMPACT
SENTIMENT
PBM : Nasdaq
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
clinical trial low float
IMPACT
SENTIMENT
COSM : Nasdaq
Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity
clinical trial low float
IMPACT
SENTIMENT
OSTX : NYSE
OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer
clinical trial
IMPACT
SENTIMENT
SONN : Nasdaq
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
clinical trial low float
IMPACT
SENTIMENT
HALB : OTC
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
clinical trial
IMPACT
SENTIMENT
NTBL : Nasdaq
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
clinical trial fda approval low float
IMPACT
SENTIMENT
TLSA : Nasdaq
Tiziana Life Sciences Granted FDA Fast Track Designation
clinical trial fda approval
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
clinical trial
IMPACT
SENTIMENT
MRUS : Nasdaq
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
clinical trial
IMPACT
SENTIMENT
SGMO : Nasdaq
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
clinical trial
IMPACT
SENTIMENT
PFE : NYSE
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
clinical trial
IMPACT
SENTIMENT
SAGE : Nasdaq BIIB : Nasdaq
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
clinical trial
IMPACT
SENTIMENT
NKTX : Nasdaq
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
clinical trial
IMPACT
SENTIMENT
SKYE : Nasdaq
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
clinical trial
IMPACT
SENTIMENT
AIMD : Nasdaq
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
clinical trial low float
IMPACT
SENTIMENT
VIRI : Nasdaq
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
clinical trial covid-19
IMPACT
SENTIMENT
JAGX : Nasdaq
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
clinical trial low float
IMPACT
SENTIMENT
MDAI : Nasdaq MDAIW : Nasdaq
Spectral AI Adds Three New Clinical Trial Sites To Expedite Emergency Department Patient Enrollment
clinical trial AI low float
IMPACT
SENTIMENT
ENLV : Nasdaq
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
clinical trial
IMPACT
SENTIMENT
BCAB : Nasdaq
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
clinical trial fda approval
IMPACT
SENTIMENT
ZIMV : Nasdaq
ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components
clinical trial fda approval
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
clinical trial
IMPACT
SENTIMENT
MESO : Nasdaq
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
clinical trial fda approval
IMPACT
SENTIMENT
SCNI : Nasdaq
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
clinical trial
IMPACT
SENTIMENT
WBA : Nasdaq
Walgreens Receives BARDA Project NextGen Award to Conduct Novel COVID-19 Decentralized Clinical Study
clinical trial covid-19
IMPACT
SENTIMENT
SCYX : Nasdaq
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
clinical trial
IMPACT
SENTIMENT
ASXC : NYSE
Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology
clinical trial fda approval
Today's News - Full List